BMY Stock Recent News
BMY LATEST HEADLINES
Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.
Bristol Myers Squibb said on Monday its experimental drug to treat a type of heart disease did not meet the main goals in a late-stage study.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial.
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. Food and Drug Administration Approves Opdivo plus Yervoy as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma.
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
The Company spend billions to produce 100% of its key medicines for Americans in the U.S.
Most dividend investors seek solid passive income streams from quality dividend stocks.